Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy
- PMID: 37261809
- DOI: 10.1001/jamaophthalmol.2023.2307
Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy
Comment on
-
Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.JAMA Ophthalmol. 2023 Jul 1;141(7):658-666. doi: 10.1001/jamaophthalmol.2023.2098. JAMA Ophthalmol. 2023. PMID: 37261816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
